B Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51

Transcription

1 Index Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, gastric. See also Gastric cancer. D2 nodal dissection for Adjuvant therapy, for gastric cancer, impact of D2 dissection on results of, 75 strategies in gastric cancer, chemoradiation, chemotherapy, perioperative chemotherapy, targeted, of gastrointestinal stromal tumor of stomach, Anaplasma lymphoma kinase, in targeted therapy of lung cancer, Angiogenesis inhibitors, clinical trials in advanced gastric cancer, monoclonal antibodies, receptor tyrosine kinase inhibitors, Asia, gastric cancer in. See Eastern experience. B Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51 C CDH1 genetic testing, for hereditary diffuse gastric cancer, minimum age for, Cell cycle inhibitors, in gastric cancer therapy, 122 Cell cycle regulatory genes, individual genetic alteration as marker in lung cancer, Chemoradiation, adjuvant, for gastric cancer, neoadjuvant, for gastric cancer, Chemotherapy, clinical trials in advanced gastric cancer, preoperative and postoperative for gastric cancer, adjuvant strategies, neoadjuvant strategies, ongoing trials, rationale for, 100 selection of treatment strategy, treatment planning and surgery, 100 Classification, of gastric cancer, role of endoscopy in, 1 3 CLEAN-NET, full-layer resection for gastric cancer with, Clinical trials. See Trials. D D1 nodal dissection, trials in gastric cancer, D2 nodal dissection, for gastric cancer, impact on results of adjuvant therapy, Surg Oncol Clin N Am 21 (2012) doi: /s (11) surgonc.theclinics.com /12/$ see front matter ª 2012 Elsevier Inc. All rights reserved.

2 178 Index D2 nodal (continued) standard and modified, for gastric adenocarcinoma, definition of nodal stations and, future of, 69 indications for modifications of, learning curve and surgical quality concerns, Maruyama index and, technique, trials in gastric cancer, Diffuse gastric cancer, hereditary. See Hereditary diffuse gastric cancer. E E-cadherin gene (CDH1), in hereditary diffuse gastric cancer, 35 East-West differences, in gastric cancer diagnosis and staging, in gastric cancer surgery, overall survival in clinical trials, stage-specific results of resected cancers, Eastern experience, with gastric cancer, compared with Western, overall survival in clinical trials, stage-specific results of resected cancers, guidelines for standard treatment, 71 impact of D2 dissection on adjuvant therapy results, 75 splenectomy, 73, 75 stage migration, 73 Endoscopic mucosal resection (EMR), basic principles, 130 choosing appropriate lesions for, CLEAN-NET, development of, 130 evaluation of lateral margins of tumor during, 132 for in situ and T-1 gastric cancer, trials of, full-layer resection, techniques, Endoscopic submucosal dissection (ESD), basic principles, 130 choosing appropriate lesions for, CLEAN-NET, development of, 130 evaluation of lateral margins of tumor during, 132 for in situ and T-1 gastric cancer, trials of, full-layer resection, techniques, Endoscopic ultrasound (EUS), in classification and diagnosis of gastric cancer, 9 12 comparison with other imaging modalities, 10 for early gastric cancer, in metastatic disease, N stage, 10 T stage, 9 10 Endoscopy, endoscopic mucosal resection, endoscopic submucosal dissection (ESD),

3 Index 179 in gastric cancer diagnosis and staging, 1 19 classification and staging, 1 3 comparison with other imaging modalities, 10 endoscopic detection, 3 6 endoscopic ultrasound (EUS), 9 for early gastric cancer, image-enhancing technologies, 6 9 linitis plastica, metastatic disease, N stage, 10 screening, T stage, 9 10 screening, in hereditary diffuse gastric cancer, Epidemiology, of hereditary diffuse gastric cancer, 37 Epidermal growth factor (EGF) receptor, in targeted therapy of lung cancer, phase I and II clinical trials of targeted gastric cancer therapy, Excision repair cross complementing 1, individual genetic alteration as marker in lung cancer, 163 F Familial gastric cancer. See Hereditary diffuse gastric cancer. Fertility issues, with total gastrectomy for hereditary diffuse gastric cancer, 51 Full-layer resection, of gastric cancer, endoscopic and laparoscopic, 135 with CLEAN-NET, G Gastrectomy, total, D2 nodal dissection for distal and, in hereditary diffuse gastric cancer, management in teenage years, mortality and morbidity risks, 49 prognosis and follow-up after, 50 staging and technical aspects, routine, versus subtotal gastrectomy, results of trials, Gastric cancer, chemotherapy, preoperative and postoperative, adjuvant strategies, neoadjuvant strategies, ongoing trials, rationale for, 100 selection of treatment strategy, treatment planning and surgery, 100 Eastern experience with, guidelines for standard treatment, 71 impact of D2 dissection on adjuvant therapy results, 75 overall survival in clinical trials in East and West, splenectomy, 73, 75 stage migration, 73 stage-specific results of resected cancers in East and West, endoscopic diagnosis and staging, 1 19

4 180 Index Gastric (continued) classification and staging, 1 3 comparison with other imaging modalities, 10 endoscopic detection, 3 6 endoscopic ultrasound (EUS), 9 EUS for early gastric cancer, image-enhancing technologies, 6 9 linitis plastica, metastatic disease, N stage, 10 screening, T stage, 9 10 endoscopic mucosal resection (EMR) and submucosal dissection (ESD), basic principles, 130 choosing appropriate lesions for, CLEAN-NET, development of, 130 EMR techniques-133, 132 ESD techniques-133, evaluation of lateral margins of tumor during, 132 full-layer resection, gastrointestinal stromal tumors (GIST) of the stomach, adjuvant targeted therapy, laparoscopic and open resection techniques, molecular analysis, neoadjuvant targeted therapy, pathology, 23 preoperative imaging, 22 resistance to targeted therapy, staging, hereditary diffuse, CDH1 genetic testing and mutation searching, consensus guidelines, 36 epidemiology, risk assessment, and penetrance, 37 genetics of, minimum age for genetic testing and intervention, models of, pathology of, surveillance and screening gastroscopy in, total gastrectomy in, laparoscopic resection of, Western experience with, evolving experience with minimally invasive surgery for, future applications, 154 indications and contraindications, learning curve, rationale for diagnostic laparoscopy and cytology, 142 results and outcomes, phase I and II clinical trials, cell cycle inhibitors, 122 chemotherapy in advanced cancers, histone deacetylase inhibitors, 121

5 Index 181 inhibitors of angiogenesis, mammalian target of rapamycin (mtor) and its inhibition, 120 mesenchymal-epithelial transition factor, 121 others, 122 strategies targeting epidermal growth factor receptor, standard D2 and modified nodal dissection for adenocarcinoma, definition of nodal stations and, future of, 69 indications for modifications of, learning curve and surgical quality concerns, Maruyama index and, technique, surgery, implications of trials, East-West differences in diagnosis and staging, extended para-aortic node dissection, extent of lymphadenectomy, D1 vs. D2, extent of resection, total vs. subtotal gastrectomy, future trails, planning a low Maruyama index operation, role of endoscopic mucosal/submucosal resection, Gastrointestinal stromal tumors (GIST), of the stomach, adjuvant targeted therapy, laparoscopic and open resection techniques, molecular analysis, neoadjuvant targeted therapy, pathology, 23 preoperative imaging, 22 resistance to targeted therapy, staging, Gastroscopy, screening with, in hereditary diffuse gastric cancer, Gene arrays, individual genetic alteration as marker in lung cancer, Genetic alterations, individual molecular markers in lung cancer, cell cycle regulatory genes, excision repair cross-complementing 1, 163 gene arrays, k-ras, p53, 162 Genetics, of hereditary diffuse gastric cancer, GIST. See Gastrointestinal stromal tumor. H Helicobacter pylori eradication, in hereditary diffuse gastric cancer, 51 Her2 (erb2), phase I and II clinical trials of targeted gastric cancer therapy, 120 Hereditary diffuse gastric cancer, CDH1 genetic testing and mutation searching, consensus guidelines, 36 epidemiology, risk assessment, and penetrance, 37 genetics of, minimum age for genetic testing and intervention, models of, 43 45

6 182 Index Hereditary (continued ) pathology of, surveillance and screening gastroscopy in, total gastrectomy in, Histone deacetylase inhibitors, in gastric cancer therapy, 121 I Imaging, preoperative, of gastrointestinal stromal tumor of stomach, 22 Imatinib, resistance to, in targeted therapy for gastrointestinal stromal tumors, K k-ras, individual genetic alteration as marker in lung cancer, L Laparoscopic resection, of gastric carcinoma, Western experience with, evolving experience with minimally invasive surgery for, future applications, 154 indications and contraindications, learning curve, rationale for diagnostic laparoscopy and cytology, 142 results and outcomes, of gastrointestinal stromal tumor of stomach, Learning curve, for D2 nodal dissection, for laparoscopic resection of gastric carcinoma, Linitis plastica, endoscopic appearance of, Lobular breast cancer, managing risk of, in hereditary diffuse gastric cancer, 51 Lung cancer, molecular markers in, individual genetic alterations, cell cycle regulatory genes, excision repair cross-complementing 1, 163 gene arrays, k-ras, p53, 162 micrornas, personalized treatment, current trials of, proteomics, 167 tyrosine kinases and targeted therapies, anaplasmic lymphoma kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor, 166 Lymphadenectomy. See also D2 nodal dissection. extended para-aortic node dissection, extent of, trials of D1 vs. D2, M Mammalian target of rapamycin (mtor), phase I and II clinical trials of targeted gastric cancer therapy, 120 Maruyama index (MI), for D2 nodal dissection, planning a low MI operation, Mesenchymal-epithelial transition factor, in gastric cancer therapy, 121 Metastatic disease, in gastric cancer, role of endoscopy, 10 11

7 Index 183 MicroRNAs, in lung cancer prognostication, Minimally invasive techniques, endoscopic diagnosis and staging of gastric cancer, 1 19 endoscopic mucosal resection (EMR) and submucosal dissection (ESD), laparoscopic resection of gastric cancer, Molecular analysis, of gastrointestinal stromal tumor of stomach, 22 Molecular markers, in lung cancer, individual genetic alterations, cell cycle regulatory genes, excision repair cross-complementing 1, 163 gene arrays, k-ras, p53, 162 micrornas, personalized treatment, current trials of, proteomics, 167 tyrosine kinases and targeted therapies, anaplasmic lymphoma kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor, 166 Monoclonal antibodies, clinical trials in advanced gastric cancer, Mutation searching, in testing for hereditary diffuse gastric cancer, N Neoadjuvant therapy, strategies for gastric cancer, targeted, of gastrointestinal stromal tumor of stomach, Nodal dissection. See D2 nodal dissection. Nodal stations, around the stomach, definition of, O Open resection, of gastrointestinal stromal tumor of stomach, P p53, individual genetic alteration as marker in lung cancer, 162 Para-aortic node dissection, extended, in gastric cancer, Pathology, of hereditary diffuse gastric cancer, Penetrance, of hereditary diffuse gastric cancer, 37 Prophylactic gastrectomy, in hereditary diffuse gastric cancer, Proteomics, in lung cancer prognostication, 167 Q Quality control, surgical, for D2 nodal dissection, R Radiation therapy. See Chemoradiation. Resection, laparoscopic and open, of gastrointestinal stromal tumor of stomach, Resistance, to targeted therapy for gastrointestinal stromal tumors, Risk assessment, in hereditary diffuse gastric cancer, 37

8 184 Index S Screening, for gastric cancer, role of endoscopy, with gastroscopy in hereditary diffuse gastric cancer, Splenectomy, in gastric cancer, 73, 75 Stage migration, in gastric cancer, source of, Staging, of gastric cancer, East-West differences in, of gastric cancer, role of endoscopy in, 1 3 of gastrointestinal stromal tumor. of stomach, Surgery, endoscopic. See Endoscopy and specific procedures. for gastric cancer, implications of clinical trials, East-West differences in diagnosis and staging, extended para-aortic node dissection, extent of lymphadenectomy, D1 vs. D2, extent of resection, total vs. subtotal gastrectomy, future trails, planning a low Maruyama index operation, role of endoscopic mucosal/submucosal resection, laparoscopic. See Laparoscopic resection. standard D2 and modified nodal dissection for gastric adenocarcinoma, definition of nodal stations and, future of, 69 indications for modifications of, learning curve and surgical quality concerns, Maruyama index and, technique, Surveillance, in hereditary diffuse gastric cancer, Survival, overall, in gastric cancer clinical trials in the East and West, T Targeted therapy, of gastric cancer, phase I and II clinical trials of, cell cycle inhibitors, 122 epidermal growth factor receptor, histone deacetylase inhibitors, 121 inhibitors of angiogenesis, mammalian target of rapamycin (mtor) and its inhibition, 120 mesenchymal-epithelial transition factor, 121 others, 122 of gastrointestinal stromal tumor of stomach, adjuvant, neoadjuvant, resistance to, tyrosine kinases in lung cancer, anaplasmic lymphoma kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor, 166 Trials, ongoing, in chemotherapy for gastric cancer, phase I and II clinical, for gastric cancer, cell cycle inhibitors, 122 chemotherapy in advanced cancers, histone deacetylase inhibitors, 121

9 Index 185 inhibitors of angiogenesis, mammalian target of rapamycin (mtor) and its inhibition, 120 mesenchymal-epithelial transition factor, 121 others, 122 strategies targeting epidermal growth factor receptor, surgical for gastric cancer, implications of, East-West differences in diagnosis and staging, extended para-aortic node dissection, extent of lymphadenectomy, D1 vs. D2, extent of resection, total vs. subtotal gastrectomy, future trails, planning a low Maruyama index operation, role of endoscopic mucosal/submucosal resection, Tyrosine kinase inhibitors, clinical trials in advanced gastric cancer, resistance to, in targeted therapy for gastrointestinal stromal tumors, Tyrosine kinases, and targeted therapies in lung cancer, anaplasmic lymphoma kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor, 166 U Ultrasound, endoscopic. See Endoscopic ultrasound. V Vascular endothelial growth factor (VEGF) receptor, in targeted therapy of lung cancer, 166 W Western experience. See also East-West differences., with laparoscopic resection of gastric carcinoma, evolving experience with minimally invasive surgery for, future applications, 154 indications and contraindications, learning curve, rationale for diagnostic laparoscopy and cytology, 142 results and outcomes,